Explore 3 Stock Ideas & Industry Insights Download Free Report

News

TransMedics (Nasdaq: TMDX) Expands Organ Transport Network in Italy with Mercedes-Benz Collaboration

TransMedics Group, Inc. (Nasdaq:TMDX), a medical technology company focused on organ transplant therapy, announced a strategic collaboration with Mercedes-Benz Group AG to introduce a fleet of purpose-built Mercedes-Benz V-Class vehicles dedicated to organ transportation across Italy. This initiative aligns with TransMedics’ plan to replicate …

Team Kalkine | 22 September 2025

Pearson (NYSE: PSO) Stock Downgraded to “Hold” Rating by Wall Street Zen

Wall Street Zen downgraded shares of Pearson plc (NYSE:PSO) from a “Buy” rating to a “Hold” rating in a research note issued on Saturday. The revision comes amid recent mixed analyst coverage, with some firms maintaining more cautious positions while others have upgraded the …

Team Kalkine | 22 September 2025

Weekly Market Wrap: Fed Cuts, Record Highs, Commodities Swings, and TikTok Deal Progress

Last week, the Dow rose 1.05%, the S&P 500 climbed 1.22%, and the Nasdaq Composite jumped 2.21%, with all three indexes reaching new record highs. The rally was driven by the Fed’s expected 25-basis-point rate cut—its first since December—along with signals of two more …

Team Kalkine | 22 September 2025

Daily Market Snapshot: Fed Easing Shapes Equities, Commodities, and Yields

U.S. stocks rose Thursday, with the Dow up 0.27%, the S&P 500 gaining 0.48%, and the Nasdaq climbing 0.94%, driven by strength in technology, industrials, and communication services. Intel surged 23% after Nvidia announced a $5 billion chip partnership, lifting Nvidia 3.5%, while Palantir, …

Team Kalkine | 19 September 2025

Skye Bioscience (Nasdaq:SKYE) Reports Phase 1b Nimacimab Results in MASLD Patients

Skye Bioscience, Inc. (Nasdaq:SKYE), a clinical-stage biotechnology company developing therapies for obesity and metabolic health disorders, presented results from its Phase 1b study of nimacimab at the European Association for the Study of Diabetes (EASD) Annual Meeting. The trial evaluated nimacimab in subjects with …

Team Kalkine | 19 September 2025

CytomX Therapeutics (NASDAQ: CTMX) Stock Rating Upgraded by Barclays

CytomX Therapeutics, Inc. (NASDAQ:CTMX), an oncology-focused biopharmaceutical company, received an upgrade from Barclays research analysts, moving its rating to "strong-buy,". This marks the latest in a series of analyst actions on the stock.

Aditi Sarkar | 19 September 2025

Lam Research (NASDAQ:LRCX) Q4 FY2025 Results: Revenue Growth and Margins Improve

Lam Research Corporation (NASDAQ:LRCX) reported results for the quarter ended June 29, 2025, showing sequential and year-on-year growth across revenue, earnings, and margins. Quarterly revenue reachedUS$5.171 billion, representing a 9.6% increase from the March quarter and a 33.6% rise compared to the same period …

Team Kalkine | 18 September 2025

Markets React to Fed’s First Rate Cut of 2025 Amid Mixed Sector and Commodity Moves

US stocks swung on Wednesday after the Fed’s 25bps cut and guidance for two more reductions this year. The Dow gained over 300 points on strength in consumer staples and financials, while the S&P 500 and Nasdaq 100 edged lower as Nvidia and Broadcom …

Team Kalkine | 18 September 2025

Baker Hughes (NASDAQ:BKR) Target Price Raised as Analysts Update Ratings

Baker Hughes (NASDAQ:BKR) had its price target increased by Capital One Financial, which lifted its objective from USD 49.00 to USD 53.00 in a report issued Tuesday. The firm maintained an “overweight” rating, with the new price objective implying a potential upside of 12.13% …

Aditi Sarkar | 17 September 2025

Biogen (Nasdaq: BIIB) Gains EU Approval for ZURZUVAE in Post-Partum Depression

Biogen Inc. (Nasdaq: BIIB) announced that the European Commission (EC) has granted marketing authorization for ZURZUVAE® (zuranolone) for the treatment of post-partum depression (PPD) in adults following childbirth. The decision makes ZURZUVAE the first and only treatment specifically indicated for PPD in the European …

Team Kalkine | 17 September 2025
Support

Hi! How can we help you today?

Loading…